Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Celltrion (068270) – Yuanta Securities | New Biosimilar Growth · Facility Expansion · CMO Capacity Readiness / 2026-05-07 Research
  • [Research] Samsung SDI (006400) – iM Securities | Surging AIDC ESS Demand · US Regulatory Tailwinds · Valuation Assessment / 2026-04-29 Research
  • [Research] LIG D&A (079550) – Kiwoom Securities | Defense Export Expansion · GR Turnaround · 2026E Upward / 2026-02-19 Research
  • [Research] Samsung SDI (006400) – Mirae Asset | Operating Profit Upgrades · Core Turnaround · Prismatic Competitiveness / 2026-07-31 Research
  • [Research] Alteogen (196170) – Hana Securities | New ALT-B4 Deal Signed · Qlex Prescription Surge · SC Conversion Acceleration / 2026-08-06 Research
  • [Research] SK hynix (000660 / SKHY) – Hyundai Motor | Supply Shortage · Memory ASP · Profitability / 2026-01-30 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q4 2024 Earnings Presentation / 2025-01-24 IR Room
  • [Research] SK hynix (000660 / SKHY) – Kyobo | Agentic AI · High-Value Memory · Pricing Momentum / 2026-04-24 Research

[Research] LIG D&A (079550/KS) – SK Securities | 1Q26 Earnings Beat · Overdone Correction · Global Demand Expansion / 2026-05-08

Posted on May 8, 2026August 21, 2026 By ksb220805@gmail.com

Brokerage : SK Securities

Analyst : Shane Han, RA Seoyoung Ko

Investment Rating : BUY (Maintain)

Target Price : KRW 1,150,000 (Maintain)

Core Momentum : Substantial 1Q26 earnings beat driven by high-margin export mix, 70-80% capacity utilization headroom, and structural Q*P compounding supported by 2026-2027 CapEx investments

1. [Valuation & Key Financial Metrics]

  • Investment Rating & Target Price: Rating BUY (Maintain), Target Price KRW 1,150,000 (Maintain), Current Price KRW 866,000 (As of May 7, 2026), Upside Potential 32.8%
  • Valuation Methodology: Target price derived by applying a Target P/E multiple of 40x to the 2028 estimated EPS of KRW 28,481
  • 2026 Full-Year Forecasts & Consensus Comparison:
    • New Forecast: Revenue KRW 5,065 Billion, Operating Profit KRW 469 Billion (OPM 9.3%), Controlling Net Profit KRW 371 Billion (Net Margin 7.3%)
    • Consensus Comparison: Outperforming consensus estimates across Revenue (+0.3% vs. KRW 5,048 Billion), Operating Profit (+5.9% vs. KRW 443 Billion), and Controlling Net Profit (+0.5% vs. KRW 369 Billion)
    • Full-year OPM is expected to exceed the company’s conservative annual guidance of 7% (and export mix guidance of 25% or below)
  • Stock & Corporate Data: KOSPI 7,490.05pt, 52-Week High KRW 1,020,000, 60-Day Avg Daily Trading Value KRW 367 Billion, Outstanding Shares 22.0 Million shares, Market Cap KRW 19,052 Billion, Foreign Ownership 23.67%, Major Shareholders LIG & 8 affiliated parties (38.21%), National Pension Service (9.67%)

2. [Market Opportunities & Business Outlook]

  • 1Q26 Earnings Review:
    • Consolidated revenue reached KRW 1,167.9 Billion (+28.7% YoY, -16.9% QoQ) and operating profit recorded KRW 171.1 Billion (+56.1% YoY, +342.4% QoQ, OPM 14.6%), significantly beating consensus (KRW 117.3 Billion) with no one-off items.
    • Core Drivers: Early delivery of Korean military-allocated volumes to the UAE due to the Iran war context, combined with the recognition of high-margin follow-on contracts (maintenance and spare parts).
  • Market Misperceptions & Correction Context:
    • Post-earnings price correction following the maintenance of the full-year 7% OPM guidance is viewed as excessive; high interceptor consumption rates indicate potential for additional volume deliveries across remaining quarters, supporting full-year earnings above guidance.
  • Production Capacity & Pipeline Catalysts:
    • Operating at a 70–80% utilization rate, providing operational headroom for accelerated deliveries and additional orders.
    • Annual CapEx of ~KRW 300 Billion planned for both 2026 and 2027, with revenue contributions from expanded capacity expected in 2028–2029.
    • Inflow of inquiries for Cheongung-II across Middle Eastern nations, alongside growing interest for Haegung (K-SAAM) in Southeast Asia, supporting long-term volume and pricing growth to alleviate valuation burdens.

Editor’s Comment (Perspective)

The covering analyst views LIG D&A not as an enterprise constrained by conservative management guidance (7%), but as an agile defense leader positioned for sustained compounding driven by proven profitability in follow-on support contracts and ample 70–80% utilization headroom. This perspective places primary importance on potential follow-on deliveries across 2026, the KRW 600 Billion total CapEx expansion across 2026–2027, and expanding pipelines for Cheongung-II across Middle Eastern nations and Haegung in Southeast Asia over near-term market sentiment swings.

To verify whether this investment thesis continues to materialize, primary focus should be directed toward sustaining high export profitability across remaining quarters to achieve the projected 9.3% full-year OPM, contract awards for Cheongung-II in the Middle East and Haegung in Southeast Asia, and the execution progress of the 2026–2027 manufacturing capacity expansions. These operational milestones can be monitored through upcoming quarterly earnings releases, corporate IR disclosures, contract award filings, and official periodic reports.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Defense

Post navigation

Previous Post: [Research] LIG D&A (079550) – Eugene Investment & Securities | Non-Cheongung Potential · High-margin Legacy Defense · Earnings Surprise / 2026-05-08
Next Post: [Research] LIG D&A (079550) – Shinhan Securities | 1Q26 Surprise · Demand Surge · Long-term Compounding / 2026-05-08

Related Posts

  • [Research] SK hynix (000660 / SKHY) – Daishin | ADR Listing · HBM4 · Valuation Re-rating / 2026-07-07 Research
  • [Research] LIG D&A (079550) – Kiwoom Securities | Order Visibility · Production Expansion · Middle East Deliveries / 2026-08-07 Research
  • [Research] Hanwha Ocean (042660) – iM Securities | Merchant Profit Surprise · Special Ship Sentiment · Valuation De-rating / 2026-07-28 Research
  • [Research] Alteogen (196170) – Shinhan Securities | Halozyme Patent Invalidated · Key Overhangs Materially Eased · Target Price Raised / 2026-05-14 Research
  • [Research] Samsung Electro-Mechanics (009150) – iM Securities | Silicon Capacitor LTA · Fabless Model · SOTP Re-rating / 2026-05-21 Research
  • [Research] SK hynix (000660 / SKHY) – Shinhan | DRAM Supply Shortage · Supplier Pricing Power · HBM3E / 2026-01-05 Research
  • [Research] Samsung Biologics (207940) – Kiwoom Securities | Plant 5 H2 Revenue Recognition · US Site Cost Control · 2026 Profitability Defense / 2026-01-07 Research
  • [Research] Hanwha Ocean (042660) – Kiwoom | Merchant Earnings Growth · 2H Order Momentum · US Naval Defense / 2026-07-15 Research
  • [Research] Samsung SDI (006400) – Hanwha Investment & Securities | US ESS Surges · 4Q LFP Ramp-Up · Cyclical Bottom Passed / 2026-02-03 Research
  • [Research] LigaChem Biosciences (141080) – Yuanta Securities | Payload Chemistry · Safety Profile · Differentiation / 2025-05-22 Research
  • [IR] SK hynix (000660 / SKHY) – Q4 2023 Earnings Presentation / 2024-01-25 IR Room
  • [Research] Samsung Biologics (207940) – Kiwoom Securities | Plant 5 & Rockville Ramp-up · Guidance Upside · 4Q Earnings Concentration / 2026-07-24 Research
  • [Research] SK hynix (000660 / SKHY) – Hana | Commodity DRAM Pricing · LTA · Multiple Expansion / 2026-06-26 Research
  • [Research] ABL Bio (298380) – DS Investment & Securities | Sanofi Strategy · Grabody B Validity · Muscle Shuttle Expansion / 2026-02-02 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme